Listed

Elite Pharmaceuticals Inc

ELTPOTCCIK 1053369HealthcareFiscal year ends Mar 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$32.4m, Q1 FY2027
Operating income$7.5m, Q1 FY2027
Net income$5.9m, Q1 FY2027
Elite Pharmaceuticals Inc, income statement, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31Q4 FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30
Revenue$m14.2Revenue, Q2 FY2024, three months to 2023-09-30$14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure15.5Revenue, Q3 FY2024, three months to 2023-12-31$15.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure17.9Revenue, Q4 FY2024, three months to 2024-03-31$17.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure18.8Revenue, Q1 FY2025, three months to 2024-06-30$18.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure18.9Revenue, Q2 FY2025, three months to 2024-09-30$18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure14.4Revenue, Q3 FY2025, three months to 2024-12-31$14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure32.0Revenue, Q4 FY2025, three months to 2025-03-31$32.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure40.2Revenue, Q1 FY2026, three months to 2025-06-30$40.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure36.3Revenue, Q2 FY2026, three months to 2025-09-30$36.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure31.6Revenue, Q3 FY2026, three months to 2025-12-31$31.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure40.7Revenue, Q4 FY2026, three months to 2026-03-31$40.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure32.4Revenue, Q1 FY2027, three months to 2026-06-30$32.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Cost of revenue$m7.7Cost of revenue, Q2 FY2024, three months to 2023-09-30$7.7m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure8.5Cost of revenue, Q3 FY2024, three months to 2023-12-31$8.5m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure9.8Cost of revenue, Q4 FY2024, three months to 2024-03-31$9.8m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure10.3Cost of revenue, Q1 FY2025, three months to 2024-06-30$10.3m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure10.7Cost of revenue, Q2 FY2025, three months to 2024-09-30$10.7m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure8.2Cost of revenue, Q3 FY2025, three months to 2024-12-31$8.2m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure14.7Cost of revenue, Q4 FY2025, three months to 2025-03-31$14.7m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure13.0Cost of revenue, Q1 FY2026, three months to 2025-06-30$13.0m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure22.2Cost of revenue, Q2 FY2026, three months to 2025-09-30$22.2m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure18.6Cost of revenue, Q3 FY2026, three months to 2025-12-31$18.6m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure20.0Cost of revenue, Q4 FY2026, three months to 2026-03-31$20.0m. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure18.8Cost of revenue, Q1 FY2027, three months to 2026-06-30$18.8m. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Gross profit$m6.4Gross profit, Q2 FY2024, three months to 2023-09-30$6.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure7.0Gross profit, Q3 FY2024, three months to 2023-12-31$7.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure8.1Gross profit, Q4 FY2024, three months to 2024-03-31$8.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure8.5Gross profit, Q1 FY2025, three months to 2024-06-30$8.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure8.2Gross profit, Q2 FY2025, three months to 2024-09-30$8.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure6.1Gross profit, Q3 FY2025, three months to 2024-12-31$6.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure17.3Gross profit, Q4 FY2025, three months to 2025-03-31$17.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure27.2Gross profit, Q1 FY2026, three months to 2025-06-30$27.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure14.1Gross profit, Q2 FY2026, three months to 2025-09-30$14.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure13.0Gross profit, Q3 FY2026, three months to 2025-12-31$13.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure20.8Gross profit, Q4 FY2026, three months to 2026-03-31$20.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure13.5Gross profit, Q1 FY2027, three months to 2026-06-30$13.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Research and development$m2.6Research and development, Q2 FY2024, three months to 2023-09-30$2.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure1.4Research and development, Q3 FY2024, three months to 2023-12-31$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure1.7Research and development, Q4 FY2024, three months to 2024-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure2.2Research and development, Q1 FY2025, three months to 2024-06-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure2.0Research and development, Q2 FY2025, three months to 2024-09-30$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure1.8Research and development, Q3 FY2025, three months to 2024-12-31$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure2.0Research and development, Q4 FY2025, three months to 2025-03-31$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure1.7Research and development, Q1 FY2026, three months to 2025-06-30$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure1.4Research and development, Q2 FY2026, three months to 2025-09-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure1.0Research and development, Q3 FY2026, three months to 2025-12-31$1.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure1.6Research and development, Q4 FY2026, three months to 2026-03-31$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure2.0Research and development, Q1 FY2027, three months to 2026-06-30$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Operating income$m1.9Operating income, Q2 FY2024, three months to 2023-09-30$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure3.5Operating income, Q3 FY2024, three months to 2023-12-31$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure3.7Operating income, Q4 FY2024, three months to 2024-03-31$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure3.9Operating income, Q1 FY2025, three months to 2024-06-30$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure3.5Operating income, Q2 FY2025, three months to 2024-09-30$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure1.1Operating income, Q3 FY2025, three months to 2024-12-31$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure11.2Operating income, Q4 FY2025, three months to 2025-03-31$11.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure21.7Operating income, Q1 FY2026, three months to 2025-06-30$21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure8.2Operating income, Q2 FY2026, three months to 2025-09-30$8.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure9.0Operating income, Q3 FY2026, three months to 2025-12-31$9.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure10.2Operating income, Q4 FY2026, three months to 2026-03-31$10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure7.5Operating income, Q1 FY2027, three months to 2026-06-30$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Interest expense$m0.1Interest expense, Q2 FY2024, three months to 2023-09-30$130.4k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure0.1Interest expense, Q3 FY2024, three months to 2023-12-31$121.6k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure0.2Interest expense, Q4 FY2024, three months to 2024-03-31$217.1k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-07-01, accession 0001493152-24-025829. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m(17.7)Income tax, Q2 FY2024, three months to 2023-09-30−$17.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure(0.8)Income tax, Q3 FY2024, three months to 2023-12-31−$800.6k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure(1.3)Income tax, Q4 FY2024, three months to 2024-03-31−$1.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure0.2Income tax, Q1 FY2025, three months to 2024-06-30$232.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure1.5Income tax, Q2 FY2025, three months to 2024-09-30$1.5m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure0.2Income tax, Q3 FY2025, three months to 2024-12-31$239.2k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure2.3Income tax, Q4 FY2025, three months to 2025-03-31$2.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure5.3Income tax, Q1 FY2026, three months to 2025-06-30$5.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure2.0Income tax, Q2 FY2026, three months to 2025-09-30$2.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure2.2Income tax, Q3 FY2026, three months to 2025-12-31$2.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure2.4Income tax, Q4 FY2026, three months to 2026-03-31$2.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure1.8Income tax, Q1 FY2027, three months to 2026-06-30$1.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Net income$m14.9Net income, Q2 FY2024, three months to 2023-09-30$14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure0.7Net income, Q3 FY2024, three months to 2023-12-31$706.4k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure3.3Net income, Q4 FY2024, three months to 2024-03-31$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure0.6Net income, Q1 FY2025, three months to 2024-06-30$615.8k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure(11.0)Net income, Q2 FY2025, three months to 2024-09-30−$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure(10.9)Net income, Q3 FY2025, three months to 2024-12-31−$10.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure17.0Net income, Q4 FY2025, three months to 2025-03-31$17.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure(5.9)Net income, Q1 FY2026, three months to 2025-06-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure13.7Net income, Q2 FY2026, three months to 2025-09-30$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure18.6Net income, Q3 FY2026, three months to 2025-12-31$18.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure18.5Net income, Q4 FY2026, three months to 2026-03-31$18.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure5.9Net income, Q1 FY2027, three months to 2026-06-30$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Diluted EPS$ per share0.01Diluted EPS, Q2 FY2024, three months to 2023-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure0.00Diluted EPS, Q3 FY2024, three months to 2023-12-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figurenot reported0.00Diluted EPS, Q1 FY2025, three months to 2024-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure(0.01)Diluted EPS, Q2 FY2025, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure(0.01)Diluted EPS, Q3 FY2025, three months to 2024-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported(0.01)Diluted EPS, Q1 FY2026, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure0.01Diluted EPS, Q2 FY2026, three months to 2025-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure0.01Diluted EPS, Q3 FY2026, three months to 2025-12-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported0.01Diluted EPS, Q1 FY2027, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Basic EPS$ per share0.01Basic EPS, Q2 FY2024, three months to 2023-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure0.00Basic EPS, Q3 FY2024, three months to 2023-12-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figurenot reported0.00Basic EPS, Q1 FY2025, three months to 2024-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure(0.01)Basic EPS, Q2 FY2025, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure(0.01)Basic EPS, Q3 FY2025, three months to 2024-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported(0.01)Basic EPS, Q1 FY2026, three months to 2025-06-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure0.01Basic EPS, Q2 FY2026, three months to 2025-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure0.02Basic EPS, Q3 FY2026, three months to 2025-12-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figurenot reported0.01Basic EPS, Q1 FY2027, three months to 2026-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure

Balance sheet

Cash and equivalents$38.9m, Q1 FY2027
Shareholders' equity$104.8m, Q1 FY2027
Elite Pharmaceuticals Inc, balance sheet, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31FY20262026-03-31Q1 FY20272026-06-30
Cash and equivalents$m8.7Cash and equivalents, Q2 FY2024, at 2023-09-30$8.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure5.8Cash and equivalents, Q3 FY2024, at 2023-12-31$5.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure7.1Cash and equivalents, FY2024, at 2024-03-31$7.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2024-07-01, accession 0001493152-24-025829.Report this figure8.4Cash and equivalents, Q1 FY2025, at 2024-06-30$8.4m. XBRL concept us-gaap:Cash. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure9.6Cash and equivalents, Q2 FY2025, at 2024-09-30$9.6m. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure8.3Cash and equivalents, Q3 FY2025, at 2024-12-31$8.3m. XBRL concept us-gaap:Cash. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure11.3Cash and equivalents, FY2025, at 2025-03-31$11.3m. XBRL concept us-gaap:Cash. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure21.7Cash and equivalents, Q1 FY2026, at 2025-06-30$21.7m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure26.6Cash and equivalents, Q2 FY2026, at 2025-09-30$26.6m. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure21.1Cash and equivalents, Q3 FY2026, at 2025-12-31$21.1m. XBRL concept us-gaap:Cash. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure29.8Cash and equivalents, FY2026, at 2026-03-31$29.8m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure38.9Cash and equivalents, Q1 FY2027, at 2026-06-30$38.9m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Current assets$m34.7Current assets, Q2 FY2024, at 2023-09-30$34.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure37.2Current assets, Q3 FY2024, at 2023-12-31$37.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure40.0Current assets, FY2024, at 2024-03-31$40.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure43.2Current assets, Q1 FY2025, at 2024-06-30$43.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001493152-24-032154.Report this figure45.3Current assets, Q2 FY2025, at 2024-09-30$45.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure48.0Current assets, Q3 FY2025, at 2024-12-31$48.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure57.7Current assets, FY2025, at 2025-03-31$57.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure77.9Current assets, Q1 FY2026, at 2025-06-30$77.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure85.8Current assets, Q2 FY2026, at 2025-09-30$85.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure96.8Current assets, Q3 FY2026, at 2025-12-31$96.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure112Current assets, FY2026, at 2026-03-31$112.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure114Current assets, Q1 FY2027, at 2026-06-30$114.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Total assets$m70.7Total assets, Q2 FY2024, at 2023-09-30$70.7m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure74.7Total assets, Q3 FY2024, at 2023-12-31$74.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure83.7Total assets, FY2024, at 2024-03-31$83.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure87.8Total assets, Q1 FY2025, at 2024-06-30$87.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001493152-24-032154.Report this figure88.2Total assets, Q2 FY2025, at 2024-09-30$88.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure90.8Total assets, Q3 FY2025, at 2024-12-31$90.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure96.4Total assets, FY2025, at 2025-03-31$96.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure111Total assets, Q1 FY2026, at 2025-06-30$111.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure117Total assets, Q2 FY2026, at 2025-09-30$117.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure126Total assets, Q3 FY2026, at 2025-12-31$126.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure138Total assets, FY2026, at 2026-03-31$138.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure140Total assets, Q1 FY2027, at 2026-06-30$139.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Current liabilities$m19.1Current liabilities, Q2 FY2024, at 2023-09-30$19.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure19.2Current liabilities, Q3 FY2024, at 2023-12-31$19.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure13.0Current liabilities, FY2024, at 2024-03-31$13.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure14.0Current liabilities, Q1 FY2025, at 2024-06-30$14.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001493152-24-032154.Report this figure12.9Current liabilities, Q2 FY2025, at 2024-09-30$12.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure14.7Current liabilities, Q3 FY2025, at 2024-12-31$14.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure11.8Current liabilities, FY2025, at 2025-03-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure10.8Current liabilities, Q1 FY2026, at 2025-06-30$10.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure10.7Current liabilities, Q2 FY2026, at 2025-09-30$10.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure13.2Current liabilities, Q3 FY2026, at 2025-12-31$13.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure17.4Current liabilities, FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure30.4Current liabilities, Q1 FY2027, at 2026-06-30$30.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Total liabilities$m25.6Total liabilities, Q2 FY2024, at 2023-09-30$25.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure28.3Total liabilities, Q3 FY2024, at 2023-12-31$28.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure26.1Total liabilities, FY2024, at 2024-03-31$26.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-06-30, accession 0001641172-25-017134.Report this figure29.6Total liabilities, Q1 FY2025, at 2024-06-30$29.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001493152-24-032154.Report this figure40.9Total liabilities, Q2 FY2025, at 2024-09-30$40.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure54.3Total liabilities, Q3 FY2025, at 2024-12-31$54.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure42.9Total liabilities, FY2025, at 2025-03-31$42.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure63.7Total liabilities, Q1 FY2026, at 2025-06-30$63.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure55.7Total liabilities, Q2 FY2026, at 2025-09-30$55.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure46.1Total liabilities, Q3 FY2026, at 2025-12-31$46.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure39.4Total liabilities, FY2026, at 2026-03-31$39.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure34.8Total liabilities, Q1 FY2027, at 2026-06-30$34.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m45.1Shareholders' equity, Q2 FY2024, at 2023-09-30$45.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure46.4Shareholders' equity, Q3 FY2024, at 2023-12-31$46.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure57.6Shareholders' equity, FY2024, at 2024-03-31$57.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-06-29, accession 0001493152-26-031070.Report this figure58.3Shareholders' equity, Q1 FY2025, at 2024-06-30$58.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure47.3Shareholders' equity, Q2 FY2025, at 2024-09-30$47.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure36.4Shareholders' equity, Q3 FY2025, at 2024-12-31$36.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure53.5Shareholders' equity, FY2025, at 2025-03-31$53.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure47.7Shareholders' equity, Q1 FY2026, at 2025-06-30$47.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure61.6Shareholders' equity, Q2 FY2026, at 2025-09-30$61.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure80.3Shareholders' equity, Q3 FY2026, at 2025-12-31$80.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure98.9Shareholders' equity, FY2026, at 2026-03-31$98.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure105Shareholders' equity, Q1 FY2027, at 2026-06-30$104.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure

Cash flow

Operating cash flow$10.1m, Q1 FY2027
Capital expenditure$809.0k, Q1 FY2027
Elite Pharmaceuticals Inc, cash flow, quarterly
Line itemUnitQ2 FY20242023-09-30Q3 FY20242023-12-31Q4 FY20242024-03-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q4 FY20252025-03-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q4 FY20262026-03-31Q1 FY20272026-06-30
Operating cash flow$m(0.2)Operating cash flow, Q2 FY2024, three months to 2023-09-30−$235.9k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001493152-24-045933. Derived: 6-month figure less the 3-month figure.Report this figure(2.4)Operating cash flow, Q3 FY2024, three months to 2023-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-02-13, accession 0001493152-25-006427. Derived: 9-month figure less the 6-month figure.Report this figure2.1Operating cash flow, Q4 FY2024, three months to 2024-03-31$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure3.1Operating cash flow, Q1 FY2025, three months to 2024-06-30$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure1.5Operating cash flow, Q2 FY2025, three months to 2024-09-30$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure(1.1)Operating cash flow, Q3 FY2025, three months to 2024-12-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure3.9Operating cash flow, Q4 FY2025, three months to 2025-03-31$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure14.8Operating cash flow, Q1 FY2026, three months to 2025-06-30$14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure5.1Operating cash flow, Q2 FY2026, three months to 2025-09-30$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure(5.3)Operating cash flow, Q3 FY2026, three months to 2025-12-31−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure9.1Operating cash flow, Q4 FY2026, three months to 2026-03-31$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure10.1Operating cash flow, Q1 FY2027, three months to 2026-06-30$10.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure
Capital expenditure$mnot reportednot reported0.4Capital expenditure, Q4 FY2024, three months to 2024-03-31$403.6k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-06-30, accession 0001641172-25-017134. Derived: 12-month figure less the 9-month figure.Report this figure0.8Capital expenditure, Q1 FY2025, three months to 2024-06-30$778.5k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2024-09-30$92.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2025, three months to 2025-03-31$754.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2026, three months to 2025-06-30$218.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2025-09-30$103.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001493152-25-023477. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2026, three months to 2025-12-31$206.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-17, accession 0001493152-26-007104. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2026, three months to 2026-03-31$398.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-06-29, accession 0001493152-26-031070. Derived: 12-month figure less the 9-month figure.Report this figure0.8Capital expenditure, Q1 FY2027, three months to 2026-06-30$809.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure

Shares

Diluted shares (weighted)1.13bn, Q1 FY2027
Elite Pharmaceuticals Inc, shares, quarterly
Line itemUnitQ2 FY20232022-09-30Q3 FY20232022-12-31Q1 FY20242023-06-30Q2 FY20242023-09-30Q3 FY20242023-12-31Q1 FY20252024-06-30Q2 FY20252024-09-30Q3 FY20252024-12-31Q1 FY20262025-06-30Q2 FY20262025-09-30Q3 FY20262025-12-31Q1 FY20272026-06-30
Diluted shares (weighted)m shares1,012Diluted shares (weighted), Q2 FY2023, three months to 2022-09-301,012,228,256 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001493152-23-041124.Report this figure1,014Diluted shares (weighted), Q3 FY2023, three months to 2022-12-311,013,915,081 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-02-14, accession 0001493152-24-006661.Report this figure1,015Diluted shares (weighted), Q1 FY2024, three months to 2023-06-301,014,572,821 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0001493152-24-032154.Report this figure1,019Diluted shares (weighted), Q2 FY2024, three months to 2023-09-301,019,316,919 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001493152-24-045933.Report this figure1,024Diluted shares (weighted), Q3 FY2024, three months to 2023-12-311,024,448,445 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-02-13, accession 0001493152-25-006427.Report this figure1,076Diluted shares (weighted), Q1 FY2025, three months to 2024-06-301,076,250,204 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001493152-25-011989.Report this figure1,068Diluted shares (weighted), Q2 FY2025, three months to 2024-09-301,068,273,108 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure1,068Diluted shares (weighted), Q3 FY2025, three months to 2024-12-311,068,273,108 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure1,068Diluted shares (weighted), Q1 FY2026, three months to 2025-06-301,068,363,108 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure1,142Diluted shares (weighted), Q2 FY2026, three months to 2025-09-301,141,536,381 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001493152-25-023477.Report this figure1,141Diluted shares (weighted), Q3 FY2026, three months to 2025-12-311,140,876,178 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-02-17, accession 0001493152-26-007104.Report this figure1,129Diluted shares (weighted), Q1 FY2027, three months to 2026-06-301,128,661,497 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure

Shares outstanding: 1.08bnShares outstanding, period not labelled, at 2026-08-131,077,136,442 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037752.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. Listed shows no prices and gives no investment advice.